FDA Approved: CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION — Supplemental Application (Neos Therapeutics, LP)

View source ↗

Summary

FDA approved a supplemental application to authorize an extended-release oral suspension formulation of carbinoxamine maleate, submitted by Neos Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Conjunctivitis
• Urticaria
• Vasomotor Rhinitis

Drugs mentioned

• Carbinoxamine maleate extended-release oral suspension (carbinoxamine maleate)

Snippet

SUPPL AP for CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION (CARBINOXAMINE MALEATE)